Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533777 · ClinicalTrials.gov registry record · NA
Antegrade Versus Retrograde IV for Blood Draws
A NA study, sponsored by University of Iowa.
- Completed
- Registry status
- NA
- Development phase
- 230
- Enrollment target
NCT03533777: Completed NA study, sponsored by University of Iowa.
NCT03533777 is a NA study that has completed, run by University of Iowa. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03533777, a NA study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- NA
- Development phase
- 230 participants
- Enrollment target
Study Summary
The purpose of this study is to compare success rates of antegrade and retrograde intravenous (IV) catheters in their ability to aspirate 20 milliliter blood sample within a 2 minute time frame, 3 hours after initial insertion. Antegrade IV catheters are placed identically to conventional IV catheters, with the end of the catheter pointed toward the direction of blood flow to the heart. Retrograde catheters are placed "backwards" with the end of the catheter pointed away from the direction of venous blood flow. The hypothesis is that retrograde IVs will have a significantly higher success rate of blood draw at the 3 hour time mark without use of a proximal tourniquet.
Primary Outcome
As compared to IV catheters placed in the standard antegrade fashion, do IV catheters placed in a retrograde direction have a higher blood draw success rate 3 hours after initial insertion, without the use of a tourniquet? Investigators define "blood draw success" as the ability to aspirate 20 mL blood samples within a 2 minute time frame. It is defined as a binary outcome variable: success vs failure. For the primary comparison of success rates in the retrograde vs antegrade IV groups, chi-squa
Interventions
- OTHER Blood draw
- PROCEDURE Peripheral intravenous catheter placement
- DEVICE Peripheral intravenous catheter
- DRUG To keep open (TKO) infusion of 0.9% normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2018-06-22 |
| Est. Completion | 2019-06-19 |
| Phase | NA |
What the finished NCT03533777 record still lists
NCT03533777 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 4 interventions - of which Blood draw is the first listed.
NCT03533777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03533777 about?
NCT03533777 is a clinical study titled "Antegrade Versus Retrograde IV for Blood Draws". The purpose of this study is to compare success rates of antegrade and retrograde intravenous (IV) catheters in their ability to aspirate 20 milliliter blood sample within a 2 minute time frame, 3 hours after initial insertion. Antegrade IV catheters are placed identically to conventional IV cathete...
What is the current status of trial NCT03533777?
This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2018-06-22. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT03533777?
The interventions under investigation include: Blood draw (OTHER), Peripheral intravenous catheter placement (PROCEDURE), Peripheral intravenous catheter (DEVICE), To keep open (TKO) infusion of 0.9% normal saline (DRUG).
Who is sponsoring clinical trial NCT03533777?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03533777's enrollment target sits among peer trials
230 465th of 2000 higher than 1,533 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI